Navigation Links
Corgenix Announces Expansion of Hemorrhagic Fever Virus Product Development Program
Date:7/10/2008

Recent outbreaks of the Lassa Hemorrhagic Fever in Africa show vital need

for new products that can be processed in any clinical or field lab

DENVER, July 10 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced an expansion of the collaborative effort for developing test kits for viral hemorrhagic fever (VHF) detection.

The viral products are being produced under a grant awarded by the National Institutes of Health (NIH) and were developed by Corgenix in collaboration with Tulane University, the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), BioFactura, Inc., Autoimmune Technologies, LLC and various partners in West Africa.

Joining the collaboration is Vybion, Inc., an Ithaca, N.Y., based biotechnology company. Vybion CEO Lee Henderson, Ph.D., stated, "We are pleased to be able to work with Corgenix, Tulane and the other partners. With our deep experience in protein expression from bacterial and mammalian cells and our extensive technology portfolio, we will be able to provide the commercial scale-up for the recombinant protein efforts."

"The addition of Vybion to our group is an important step in achieving full commercialization of the products developed under this collaboration," said Douglass Simpson, Corgenix President and CEO. "We already have products in the field in Africa, and with Vybion's capabilities in producing large quantities of the critical reagents, we have the supply chain necessary for full scale production of these critically important detection products."

Corgenix and the other partners have developed and applied for a patent for new recombinant proteins for Lassa virus. Lassa fever, a serious viral infection spread by contact with infected rodents, is estimated to infect 300,000 to 500,000 people per year across West Africa, with approximately 5,000 deaths. Current tests are expensive, not commercially available, can take days to return results, and usually require the culture of live Lassa virus in a high-containment laboratory to produce reagents. In some areas of Sierra Leone and Liberia, up to 16 percent of people admitted to hospitals have Lassa fever. Lassa fever is also associated with occasional epidemics, during which the case-fatality rate can reach 50 percent.

New outbreaks of the Lassa hemorrhagic fever have been reported recently. Daniel Bausch MD, MPH&TM, Director of the Mano River Union Lassa Fever Network and Tulane's Program in West Africa, observed, "We are now seeing a much broader presence of this disease in Africa. Within the past two months alone we have seen an increase in the number of cases in Nigeria, with increased fatalities. It is critical that the assays we have already developed and are using in Africa, as well as others still in our development pipeline, become fully deployed to aid in this vital effort."

Corgenix said the new tests already developed by the group can be run in just 90 minutes, and unlike other virus tests, don't require specially designed and engineered Biosafety Level 4 (BSL-4) laboratories operated by specially trained personnel. This makes the products ideal for important clinical areas such as Africa, as well as the bioterrorism concern. Under the NIH grant, Tulane has been leading a three-year study designed to develop better tests for VHFs, some of which are potential bioterrorism agents due to their high fatality rate and ease of transmission from person to person.

Robert Garry, Ph.D., Professor of Microbiology and Immunology at the Tulane University School of Medicine and Principle Investigator of the program, added, "We have been very pleased with the results of our development effort. The products have shown to be remarkably effective in clinical settings in Africa and will have a meaningful impact on the healthcare in that part of the world, but will also fill a critical gap in bioterrorism defense. Now with the addition of Vybion, Corgenix can successfully scale-up the production to address both needs."

Dr. Garry stated that the group intends to expand this program to address other important infectious agents-such as Ebola, Marburg and other hemorrhagic fever viruses-that are of concern to the public health and bioterrorism preparedness communities.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for emerging pathogens and bio-threat agents, immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at http://www.corgenix.com.

About Tulane University

Tulane University (New Orleans LA) was founded in 1834. Tulane is one of the most highly regarded and selective research universities in the United States, and is a member of the prestigious Association of American Universities. Tulane's schools and colleges offer undergraduate, graduate and professional degrees in the liberal arts, science and engineering, architecture, business, law, social work, medicine and public health and tropical medicine.

About Vybion, Inc.

Vybion (Ithaca, N.Y.) is an emerging biotechnology company with a proprietary biopharmaceutical drug pipeline and platform technology for human monoclonal antibody selection and affinity maturation. The Company's contract division has developed over 100 recombinant proteins in multiple expression systems including 10 drugs in various phases of clinical development.

About USAMRIID

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute conducts basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. While USAMRIID's primary mission is focused on the military, its research often has applications that benefit society as a whole. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command. For more information, visit http://www.usamriid.army.mil

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver
2. Corgenix Reports Third Quarter Fiscal 2008 Financial Results
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: